Trials / Terminated
TerminatedNCT02913105
Safety, Tolerability, Pharmacokinetics and Efficacy of LMB763 in Patients With NASH
A Randomized, Patient and Investigator Blinded, Placebo Controlled, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of LMB763 in Patients With Non-alcoholic Steatohepatitis (NASH)
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 122 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the present study is to assess the effects of LMB763 with respect to safety, tolerability, and on markers of liver inflammation in patients with NASH
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LMB763 | Hard Gelatin Capsules |
| DRUG | Placebo | Hard Gelatin Capsule |
Timeline
- Start date
- 2016-10-24
- Primary completion
- 2018-09-19
- Completion
- 2018-09-19
- First posted
- 2016-09-23
- Last updated
- 2021-01-05
- Results posted
- 2019-11-26
Locations
30 sites across 8 countries: United States, Australia, Georgia, Jordan, New Zealand, Puerto Rico, Switzerland, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02913105. Inclusion in this directory is not an endorsement.